Satellite Symposia
Sunday, 18 June 2017
Satellite Symposium (SAT 1)
epgonline.org
Hall 3a, 17:30 – 19:00
The future of urticaria – advances in CSU research
Chair: Marcus Maurer, Germany
Introduction: Welcome address
Marcus Maurer, Germany
Under the skin of CSU – diagnostic and prognostic biomarkers in urticaria
Martin Metz, Germany
Keeping it real: a look at the latest real-world data in CSU management
Alexander Marsland, United Kingdom
Managing relapse in CSU
Gordon Sussman, Canada
Looking beyond CSU – a round-up of recent research
Marcus Maurer, Germany
Questions from the audience
All speakers
Closing address
Marcus Maurer, Germany
Company Sponsored Satellite Symposium (SAT 2)
FAES FARMA & The MENARINI GROUP
Hall 3c, 17:30 – 19:00
A New Perspective in the Treatment of Allergies in Adults and Children: Bilastine
Chairs: Marysia Recto, Philippines & Torsten Zuberbier, Germany
Allergic Rhinitis guidelines: the seek for the Ideal Antihistamine
Piotr Kuna, Poland
The world of Urticaria: guidelines update and new evidences for Bilastine
Torsten Zuberbier, Germany
Bilastine in childhood: a new effective and safe solution for Paediatricians
Zoltán Novak, Hungary
Company Sponsored Satellite Symposium (SAT 3)
Shire International GmbH
Hall 3d, 17:30 – 19:00
Hereditary angioedema: what does the future hold?
Co-chairs: Marco Cicardi, Italy & Markus Magerl, Germany
Faculty: Emel Aygören-Pürsün, Germany
Welcome, and an introduction to hereditary angioedema (HAE)
Marco Cicardi, Italy
Challenges and current treatment options in the management of paediatric HAE patients
Markus Magerl, Germany
Future therapeutic options for the management of paediatric HAE patients
Emel Aygören-Pürsün, Germany
The future of HAE treatment: innovative therapies to address unmet needs
Marco Cicardi, Italy
Q&A and closing remarks
All faculty/co-chairs
Company Sponsored Satellite Symposium (SAT 4)
GlaxoSmithKline
Hall 3e, 17:30 – 19:00
The Asthma Journey – Right Road, Right Destination
Chair: Maritta Kilpeläinen, Finland
The building blocks for optimal asthma treatment
Maritta Kilpeläinen, Finland
Laying the foundations for improvements in therapy: Shared decision-making
Neil Martin, United Kingdom
Drawing the blueprints for correct asthma diagnosis
Peter Howarth, United Kingdom
Raising outcomes in the treatment of severe eosinophilic asthma
Neil Barnes, GSK, United Kingdom
Surveying the evidence: Effectiveness of targeted therapies in the real world
Andreas Heddini, United Kingdom
Q&A and symposium close
Maritta Kilpeläinen, Finland; Neil Barnes, United Kingdom
Company Sponsored Satellite Symposium (SAT 5)
Allergy Therapeutics plc.
Hall 3g, 17:30 – 19:00
The Best Therapies By Design
The importance of defining the optimal dose
Jörg Kleine-Tebbe, Germany
Molecular fingerprinting of complex allergoids
Erika Jensen-Jarolim, Austria
Rationale for broad spectrum grass immunotherapy
Uwe E. Berger, Austria
Defining the plateau of the efficacy for Allergen Specific Immunotherapy
Tim Higenbottam, United Kingdom
| Company Sponsored Satellite Symposium (SAT 6) Nestlé Health Science Room 101, 17:30 – 19:00 |
 |
Controversies on Special Products for Managing Cow’s Milk Protein Allergy (CMPA) in Infants – Safety and Suitability 
Chairpersons: Antonella Muraro, Italy & Arne Høst, Denmark
Choosing the most appropriate dietary management for infant with CMPA
Rosan Meyer, United Kingdom
Not all extensively hydrolysed formulas intended for CMPA are the same
Martinas Kuslys, Switzerland
New guidelines ensuring safe products for infants with CMPA – update from the EAACI Task Force on special products for CMPA
Antonella Muraro, Italy
Arne Høst, Denmark
Monday, 19 June 2017
| Company Sponsored Satellite Symposium (SAT 7) AstraZeneca Hall 3a, 17:45 – 19:15 |
A Personalized Approach to Eosinophilic Asthma: Expert Perspectives in Clinical Practice
Welcome and Introductions
Ian Pavord, United Kingdom
Challenges in Asthma Heterogeneity
Leif Bjermer, Sweden
Clinical and Patient Perspectives in Severe Eosinophilic Asthma
Arnaud Bourdin, France
The Evolving Science of Severe Asthma and Emerging Clinical Practices
Ian Pavord, United Kingdom
Panel Discussion and Audience Q&A
All
| Company Sponsored Satellite Symposium (SAT 8) DBV Technologies Hall 3d, 17:45 – 19:15 |
Investigational Epicutaneous Immunotherapy: Shaping the Future of Treating Food Allergies
Chair: Jonathan Hourihane, Ireland
Welcome and Introductions
Jonathan Hourihane, Ireland
The Unique Immune Properties of the Skin
Hugh A. Sampson, United States
Clinical Development of EPIT in Food Allergies
André C. Knulst, The Netherlands
What Are the Expectations for Peanut Allergy Immunotherapy?
Jonathan M. Spergel, United States
Conclusions and Faculty Panel Discussion
| Company Sponsored Satellite Symposium (SAT 9) CSL Behring GmbH Hall 3e, 17:45 – 19:15 |
The dawn of a new era of HAE Management
Chairs: Marco Cicardi, Italy
Timothy Craig, United States
Welcome and introduction
Marco Cicardi, Italy; Timothy Craig, United States
Unmet medical needs in HAE management
Markus Magerl, Germany
Experience with C1-INH replacement therapy for HAE management
Hilary Longhurst, United Kingdom
COMPACT: Evidence for subcutaneous C1-INH for routine prevention
Bruce Zuraw, United States
Panel discussion
All
Closing remarks
Marco Cicardi, Italy; Timothy Craig, United States
| Company Sponsored Satellite Symposium (SAT 10) Sanofi Genzyme and Regeneron Room 103a, 17:45 – 19:15 |
Evolving Concepts and Clinical Implications for Targeted Therapeutics in Asthma Patients with Overlapping Type 2 Comorbidities
Chair: William Busse, United States
Welcome and Introduction
William Busse, United States
Clinical Insights into the Management of Patients with Multiple Comorbidities: Clinical Challenges, Best Practices, and Future Directions
William Busse, United States
High Burden of Disease in Patients with Multiple Type 2 Diseases and Associated Comorbidities
David Price, United Kingdom
Lessons Learned from Immune-Epithelial Interactions in the Skin and Implications for Airway Diseases
Donald Leung, United States
Exploring the Links Between Upper and Lower Airway Inflammation and Implications for The Clinic
Claus Bachert, Belgium
Asthma Immunology – A clinical approach
Klaus Rabe, Germany
Closing Remarks and Panel Q&A
William Busse
All
| Company Sponsored Satellite Symposium (SAT 11) Teva Pharmaceuticals Room 102, 17:45 – 19:15 |
Personalising clinical management in severe asthma
Chair: Vibeke Backer, Denmark
Welcome and introduction
Vibeke Backer, Denmark
Severe asthma: idetifying those with the eosinophilic phenotype
Dave Singh, United Kingdom
What biomarkers are clinically important in the inflamed lung?
Christian Virchow, Germany
Anti-IL-5 therapy: from clinical trials to clinical practice
Guy Brusselle, Belgium
Summary and close
Vibeke Backer, Denmark
Tuesday, 20 June 2017
| Company Sponsored Satellite Symposium (SAT 12) Aimmune Therapeutics, Inc Hall 3a, 17:30 – 19:00 |
Meeting Patients’ Needs: Exploring a Path to an Approved Oral Treatment for Peanut Allergy
Chair: Clare Mills, United Kingdom
Chair’s address
Clare Mills, United Kingdom
Why do patients and families need an approved oral therapy for peanut allergy?
Sabine Schnadt, Germany
How is oral immunotherapy evolving?
Kirsten Beyer, Germany
Defining success of oral immunotherapy for Health Care Practitioners
Pablo Rodriguez del Rio, Spain
Chair’s closing remarks
| Company Sponsored Satellite Symposium (SAT 13) Sanofi Genzyme and Regeneron Hall 3g, 17:30 – 19:00 |
Advancing the Clinical Care of Patients With Persistent Atopic Dermatitis
Chair: Thomas Bieber, Germany
Welcome and Introduction
Thomas Bieber, Germany
Clinical Challenges, Best Practices, and Future Directions
Thomas Bieber, Germany
The Predisposition of Patients Living With AD: Comorbidities and Atopic March
Mark Boguniewicz, United States
Emerging Therapeutic Strategies for Atopic Dermatitis
Michael J. Cork, United Kingdom
Looking Forward – Defining Different AD Clinical Phenotypes: Biomarkers and Genotypes Associated With AD Endotypes
Thomas Bieber, Germany
Closing Remarks and Panel Q&A
Thomas Bieber, Germany
All
| Company Sponsored Satellite Symposium (SAT 14) BIOMAY AG Room 103a, 17:30 – 19:00 |
Peptide carrier fusion vaccines: A new paradigm for allergen specific immunotherapy
Chairpersons: Marianne van Hage, Sweden & Rudolf Valenta, Austria
Welcome
Rainer Henning, Austria
Limitations of current allergen extract-based AIT
Marianne van Hage, Sweden
Design of recombinant AIT vaccines based on the peptide carrier fusion technology
Rudolf Valenta, Austria
Clinical evaluation of a grass pollen allergy vaccine based on the peptide carrier fusion technology
Petra Zieglmayer, Austria
Questions & Answer